3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
56
Ovarian Neoplasms
35
Carcinoma, Hepatocellular
35
Neoplasms
25
Fallopian Tube Neoplasms
20
Carcinoma, Non-Small-Cell Lung
19
Endometrial Neoplasms
13
Glioblastoma
11
Breast Neoplasms
11
Brain Neoplasms
11
Neoplasm Metastasis
9
Colonic Neoplasms
9
Lung Neoplasms
8
Uterine Cervical Neoplasms
7
Liver Neoplasms
7
Rectal Neoplasms
6
Glioma
6
Biliary Tract Neoplasms
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Small Cell Lung Carcinoma
3
Sarcoma
3
Recurrence
3
Peritoneal Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Neoplasms
3
Interventions
atezolizumab
1
Diet, Ketogenic
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Fatty Liver
×
Bevacizumab
×
90 days
×
Clear all
NCT06096779
2026-06-01
Kirros
Genentech, Inc.
Phase 2
Recruiting
30 enrolled